InvestorsHub Logo
Followers 230
Posts 21496
Boards Moderated 2
Alias Born 08/03/2006

Re: lux1 post# 13354

Wednesday, 10/07/2015 5:30:56 AM

Wednesday, October 07, 2015 5:30:56 AM

Post# of 15766
$8 - $23, that'd be a nice start. Welcome to Investor & Analyst Day 10/7/2015 1:00 PM (ET)

http://wsw.com/webcast/cc/mstx/register.aspx?conf=cc&page=mstx&url=http%3A//wsw.com/webcast/cc/mstx/


Target price vs. sales in SCD
Some analysts say that the sales of vepoloxamer in SCD could be in the range of $300-800 million per year.
the Price/Sales ratio or P/S in healthcare sector is a number between 3 to 20. 3 for big company, 20 for small company.
Also if you suppose a P/S very conservati of 5 you have a market capitalisation in the range of $1.5-4 billion.
This market cap. gives a pps in the range $8-$23 share.


"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.